ArticleF1000Research2019
Visualization of drug target interactions in the contexts of pathways and networks with ReactomeFIViz.
Article in F1000Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- The landscape of cyclin-dependent kinase 4/6 inhibitors in solid malignancies: emphasis on immunotherapy combinatorial strategies.Medical oncology (Northwood, London, England) · 2025Review
- Effective data visualization strategies in untargeted metabolomics.Natural product reports · 2025Review
- scRank infers drug-responsive cell types from untreated scRNA-seq data using a target-perturbed gene regulatory network.Cell reports. Medicine · 2024Article
- Graph Structured Neural Networks for Perturbation Biology.bioRxiv : the preprint server for biology · 2024Article
- Enhancing the anticancer potential of metformin: fabrication of efficient nanospanlastics,International journal of pharmaceutics: X · 2023Article
- Using the Reactome Database.Current protocols · 2023Article
- Integrative analysis of drug response and clinical outcome in acute myeloid leukemia.Cancer cell · 2022Article
- A systems biology approach identifies candidate drugs to reduce mortality in severely ill patients with COVID-19.Science advances · 2022Article
- Evaluating the predictive accuracy of curated biological pathways in a public knowledgebase.Database : the journal of biological databases and curation · 2022Article
- Exploring Toxins for Hunting SARS-CoV-2 Main Protease Inhibitors: Molecular Docking, Molecular Dynamics, Pharmacokinetic Properties, and Reactome Study.Pharmaceuticals (Basel, Switzerland) · 2022Article
- The potential of a data centred approach & knowledge graph data representation in chemical safety and drug design.Computational and structural biotechnology journal · 2022Review
- Gastroprotection against Rat Ulcers byBiomolecules · 2021Article
- Blue Biotechnology: Computational Screening ofMarine drugs · 2021Article
- Two novel oxetane containing lignans and a new megastigmane fromRSC advances · 2021Article
- In Silico Mining of Terpenes from Red-Sea Invertebrates for SARS-CoV-2 Main Protease (MMolecules (Basel, Switzerland) · 2021Article
- Leveraging biochemical reactions to unravel functional impacts of cancer somatic variants affecting protein interaction interfaces.F1000Research · 2021Article
- Integrated Genomic Profiling and Drug Screening of Patient-Derived Cultures Identifies Individualized Copy Number-Dependent Susceptibilities Involving PI3K Pathway and 17q Genes in Neuroblastoma.Frontiers in oncology · 2021Article
- Article
- Illuminating biological pathways for drug targeting in head and neck squamous cell carcinoma.PloS one · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The precision medicine paradigm is centered on therapies targeted to particular molecular entities that will elicit an anticipated and controlled therapeutic response. However, genetic alterations in the drug targets themselves or in genes whose products interact with the targets can affect how well a drug actually works for an individual patient. To better understand the effects of targeted therapies in patients, we need software tools capable of simultaneously visualizing patient-specific variations and drug targets in their biological context. This context can be provided using pathways, which are process-oriented representations of biological reactions, or biological networks, which represent pathway-spanning interactions among genes, proteins, and other biological entities. To address this need, we have recently enhanced the Reactome Cytoscape app, ReactomeFIViz, to assist researchers in visualizing and modeling drug and target interactions. ReactomeFIViz integrates drug-target interaction information with high quality manually curated pathways and a genome-wide human functional interaction network. Both the pathways and the functional interaction network are provided by Reactome, the most comprehensive open source biological pathway knowledgebase. We describe several examples demonstrating the application of these new features to the visualization of drugs in the contexts of pathways and networks. Complementing previous features in ReactomeFIViz, these new features enable researchers to ask focused questions about targeted therapies, such as drug sensitivity for patients with different mutation profiles, using a pathway or network perspective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.